Floatz logo

Alintegimod

Advanced Cancer

7 Hills Pharma, LLCSmall moleculePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

1411 Active assets in the Advanced Cancer cohort.

View all 50

Same molecule, other indications

Alintegimod is also rated in:

Anaplastic Lymphoma Kinase Genomic Tumor AberrationsDormant
CCC
Indicative ·
48 / 100
View asset →
Renal Cell CancerDormant
CCC
Indicative ·
48 / 100
View asset →
ALK Genomic Tumor AberrationsDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →